Last reviewed · How we verify
nsclc nonsquamous
Approved treatments
Clinical guidelines
- FDA label — 1L
In combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. - FDA label — 1L
In combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- nsclc nonsquamous patent landscape — cliff calendar, originator estates, attackable patents
- nsclc nonsquamous treatment landscape brief
- nsclc nonsquamous treatment updates RSS
Frequently asked questions about nsclc nonsquamous
What are the treatment guidelines for nsclc nonsquamous?
FDA label publishes guidelines for nsclc nonsquamous. 2 guideline references tracked.
Related
- Treatment landscape: nsclc nonsquamous patent cliff · nsclc nonsquamous CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing